CD274 and head and neck squamous cell carcinoma: Additionally, OncoPrism-HNSCC outperformed PD-L1 CPS ≥ 20 across multiple metrics, including higher sensitivity (0.79 vs 0.64, p = 0.005) and specificity (0.70 vs 0.61, p = 0.009; Table 2).